FDA Updates Labeling on Febrile Seizure Risks i...

By João L. Carapinha

January 19, 2026

FDA Labeling Mandate on Febrile Seizure Risks In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines t...
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025
FDA Guidance on Overall Survival Assessment in Oncology Trials
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants
Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical ...
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron ...
Personalized Cancer Vaccine in High-Risk Kidney Cancer Patients
MPA Meningioma Risk: Key Insights and Implications
Diabetes Drugs Safe from Thyroid Cancer Risk, Study Finds